Printer Friendly

Using bisphosphonates to prevent hip fractures costly.


Giving bone-strengthening medication routinely to all elderly women who sustain a wrist fracture would reduce subsequent hip fractures by about a quarter, but at a cost of more than $200,000 per prevented fracture, a study showed.

In addition, expanded bisphosphonate use could cause nearly 20,000 more atypical femur fractures in this population, Dr. Suneel Bhat said at the annual meeting of the American Academy of Orthopaedic Surgeons in Las Vegas.

Dr. Bhat and associates at Thomas Jefferson University, Philadelphia, used sophisticated modeling techniques to project costs and consequences of wider prescribing of bisphosphonates for bone fragility in women 65 years and older. Distal radius fracture is known to be associated with osteoporosis in women of this age, who are then at increased risk of subsequent fracture.

Study authors drew from the medical literature and publicly available Medicare data to obtain fracture incidence data and cost information for statistical modeling. Dr. Bhat and colleagues obtained the age-specific incidence of distal radius fractures among women aged 65 and older, as well as the rates of hip fracture following wrist fractures, both for those who did and did not receive the bisphosphonate risendronate. Atypical femur fracture is a known complication of bisphosphonate treatment for some patients; the risk of this complication and medication costs were drawn from the literature.

To assess the direct costs of hip fracture treatment, the investigators used Medicare reimbursement data to price treatment components, including inpatient care as well as surgical and anesthesia services.

From these data, the investigators used a modified Monte Carlo technique to obtain a cost and incidence model. This model predicted that 357,656 lifetime subsequent hip fractures would occur in elderly women with wrist fracture; this number would drop to 262,767 with universal bisphosphonate treatment.

The cost for this savings, an aggregate $19.5 billion in drug costs, meant that each fracture prevented would cost $205,534. An additional 19,464 patients would sustain atypical femur fracture from risendronate treatment.

Average risendronate costs were estimated at $1,485/patient-year. This figure would have to fall to just $70/ patient yearly to make risendronate treatment cost effective, Dr. Bhat said.

COPYRIGHT 2015 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:RHEUMATOLOGY
Author:Oakes, Kari
Publication:Internal Medicine News
Date:Apr 15, 2015
Previous Article:New hypertension guidelines clarify prior confusion.
Next Article:Overall physical health predicts arthritis pain.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters